RTW Investments KLRS Position
Active4-Fund ConvergenceRTW Investments initiated a new position in Kalaris Therapeutics, Inc. (KLRS) in Q4 2025, holding $11.0M worth of shares across 1,300,000 shares.
KLRS is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 10.3% of float with 14.8 days to cover, indicating significant bearish positioning against RTW Investments's long thesis.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Full company profile →Short Interest
10.3%
14.8 days to cover
Frequently Asked Questions
Does RTW Investments own KLRS?
Yes. As of Q4 2025, RTW Investments holds 1,300,000 shares of Kalaris Therapeutics, Inc. (KLRS) valued at $11.0M. This data comes from their SEC 13F filing.
How many hedge funds own KLRS?
4 specialist biotech hedge funds currently hold KLRS, including Tang Capital Management, EcoR1 Capital, Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RTW Investments first buy KLRS?
RTW Investments's position in KLRS was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RTW Investments's KLRS position increasing or decreasing?
RTW Investments initiated a new position in KLRS in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KLRSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RTW InvestmentsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →